Compare WDS & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WDS | RMD |
|---|---|---|
| Founded | 1954 | 1989 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | WDS | RMD |
|---|---|---|
| Price | $16.12 | $252.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $292.27 |
| AVG Volume (30 Days) | 584.7K | ★ 893.0K |
| Earning Date | 08-18-2025 | 01-29-2026 |
| Dividend Yield | ★ 6.29% | 0.95% |
| EPS Growth | ★ 58.72 | 29.59 |
| EPS | 1.54 | ★ 9.77 |
| Revenue | ★ $13,781,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | N/A | $9.85 |
| Revenue Next Year | N/A | $7.32 |
| P/E Ratio | ★ $10.50 | $25.82 |
| Revenue Growth | ★ 9.53 | 9.36 |
| 52 Week Low | $11.26 | $199.92 |
| 52 Week High | $17.70 | $293.81 |
| Indicator | WDS | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 48.94 |
| Support Level | $16.22 | $250.37 |
| Resistance Level | $16.98 | $259.99 |
| Average True Range (ATR) | 0.22 | 5.54 |
| MACD | -0.09 | 0.57 |
| Stochastic Oscillator | 16.91 | 63.20 |
Incorporated in 1954 and named after the small Victorian town of Woodside, Woodside's early exploration focus moved from Victoria's Gippsland Basin to Western Australia's Carnarvon Basin. First LNG production from the North West Shelf came in 1984. BHP Billiton and Shell each had 40% shareholdings before BHP sold out in 1994 and Shell sold down to 34%. In 2017 Shell sold its entire shareholding. Woodside is one of the most LNG-leveraged companies globally.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.